It began as a solution to scarcity. When GLP-1 receptor agonists like Ozempic and Wegovy were first introduced, they quickly ignited a public health and media firestorm—praised for their effectiveness in treating type 2 diabetes and aiding substantial weight loss. As celebrities and social media influencers touted dramatic results, demand skyrocketed, leading to widespread shortages that left many patients—particularly those with metabolic disorders—scrambling for alternatives.
Out of this chaos emerged a workaround: compounded versions of semaglutide, the active ingredient in Ozempic and Wegovy, mixed by specialty pharmacies and distributed under varying legal interpretations. For many, this meant access. For regulators, it raised alarms.
Interest in weight loss medications, specifically GLP-1 agonists such as Ozempic, is increasing, echoing a greater emphasis on metabolic and obesity. However, compounded versions of said medications are the strongest driver toward patient accessibility. The FDA appears to have put an end to that with its withdrawal of the shortage designation. Nevertheless, companies continue finding ways to provide compounded GLP-1 drugs. How are they still doing so?
The Regulatory Turn: When Shortage Meets Policy
The FDA’s authority to allow compounded medications is rooted in the Federal Food, Drug, and Cosmetic Act, specifically under Sections 503A and 503B. These provisions enable pharmacies to compound medications not commercially available when there is a verified drug shortage. Between late 2022 and mid-2023, semaglutide was listed on the FDA’s drug shortage list, which effectively opened the door for compounding.
But in March 2024, semaglutide was quietly removed from the FDA’s shortage list. Without the shortage classification, the legal justification for compounding semaglutide became more tenuous. Yet compounded products remain widely available.
The Loophole: Sodium Salts and Semantics
Compounding pharmacies have responded creatively, often by sourcing semaglutide sodium or semaglutide acetate—chemical salt forms not found in the FDA-approved medications, which contain only the base form. This provides a gray area that some pharmacies exploit: since the active compound is technically not identical to what’s approved, it is also technically not subject to the same restrictions.
The FDA has warned that these formulations do not qualify for compounding under federal law, but enforcement has been slow. Many pharmacies market their products ambiguously or rely on offshore suppliers of raw ingredients.
Compounding for Uniqueness: The Role of B12, NAD+, and Additive Customization
Another key tactic used by compounding pharmacies to navigate regulatory scrutiny is formulation customization. By combining semaglutide with additional ingredients—most commonly vitamin B12, L-carnitine, or NAD+ (nicotinamide adenine dinucleotide)—pharmacies can argue that the resulting product is not a direct copy of a commercial drug, but a unique formulation tailored to individual patient needs.
This biochemical distinction provides more than just legal cover—it also serves a marketing purpose.
- Vitamin B12, often promoted for its energy-boosting properties, is added to counteract potential fatigue or nausea associated with GLP-1 medications. While scientific evidence for this synergy is limited, the perception of enhanced tolerability is appealing to patients.
- NAD+, a molecule involved in cellular energy and aging, is marketed as a metabolic enhancer. Some clinics position NAD+-semaglutide blends as “longevity-supportive” or “anti-aging”, though peer-reviewed evidence for these combinations is scarce.
- L-carnitine, associated with fat metabolism, is also blended into some compounded formulas, sold under proprietary brand names that further differentiate them from branded semaglutide.
While these customizations don’t change the drug’s primary action—GLP-1 receptor agonism—they provide a branding strategy for compounding pharmacies and a clinical rationale for prescribing providers who argue that such combinations are “medically necessary” or “patient-specific,” thus qualifying under Section 503A of the compounding statute.
Telehealth and the Custom Care Boom
Telehealth startups play a pivotal role in this system. By streamlining virtual consultations and offering bundled wellness programs, these companies position themselves as both providers and platforms—connecting patients to compounded GLP-1 options with names like “MetaboBalance” or “SemaLean Pro.”
For many patients, this consumer-centric model is attractive. Pricing is transparent, consultations are convenient, and formulations are framed as holistic. But critics argue that such framing can obscure regulatory gray areas and deflect scrutiny from the core issue: whether these compounded versions are clinically safe and legally compliant.
The Regulatory Response and Clinical Risks
As demand grows, so do concerns over quality control, dosing variability, and adverse effects. Compounded drugs, even when legally prepared, are not subject to the same FDA-mandated clinical trials or manufacturing standards as approved drugs. This has led to variability in efficacy, and in rare cases, harmful contaminants.
The FDA has already issued multiple warning letters to compounders over labeling and safety violations related to semaglutide formulations. Still, enforcement remains reactive rather than systemic.
Conclusion: Innovation or Exploitation?
The compounded GLP-1 market exists in a precarious balance between access and oversight, necessity and novelty. Its growth reveals not only the gaps in America’s regulatory architecture, but also the unmet demand for affordable, accessible metabolic care.
Whether these compounded formulations—with their added B12, NAD+, or marketing flourish—represent personalized innovation or commercial exploitation depends on your vantage point. For some patients, they are a lifeline. For regulators, they are a problem yet to be solved.
Until comprehensive access to FDA-approved GLP-1 therapies is both universal and affordable, these gray-market solutions will continue to thrive in the space where public health ambition collides with pharmaceutical economics.
